



**RANZCO**

The Royal Australian  
and New Zealand  
College of Ophthalmologists

# RANZCO Fluorescein and Indocyanine Green Angiography Guidelines

---

**Approved by:** Board  
**Version:** Current  
**Department:** Advocacy

**Next review date:** April 2026  
**Approval date:** April 2023  
**Policy inventory number:** 219.2023.04 01

The Royal Australian and New Zealand College of Ophthalmologists ABN 80 000 644 404  
94 - 98 Chalmers Street, Surry Hills NSW 2010 Australia **Mail to:** PO Box 92 Strawberry Hills NSW 2012  
**T** 61 2 9690 1001 **E** [ranzco@ranzco.edu](mailto:ranzco@ranzco.edu) **www.ranzco.edu**

*We acknowledge the Aboriginal and Torres Strait Islander Peoples, the Traditional Owners of Country throughout Australia and recognise their continuing connection to land, waters and community. We pay our respects to them and their cultures; and to their Elders past, present and emerging. In recognition that we are a bi-national College, we also acknowledge the Rangatiratanga of Māori as Tangata Whenua and Treaty of Waitangi partners in Aotearoa New Zealand.*

## 1 Introduction

These Guidelines have been issued by RANZCO for the guidance of ophthalmologists. They should not be used by any other persons or provided to patients as a replacement for medical advice.

## 2 Background and context

Fluorescein angiography (FA) is an extremely useful and minimally invasive diagnostic investigation that is frequently performed in ophthalmologists' private practices and ophthalmology departments. Indocyanine Green (ICG) angiography is a similar but less frequently performed investigation. Despite the generally low risks of the procedure, deaths have occurred during and following FA in both Australia and overseas. For more detailed information see Appendix A.

- a. Guidelines in eye care are neither minimal nor aspirational but represent quality eye care commensurate with knowledge as at the date of issue. These Guidelines are based on the best available scientific data and on the collective judgement and evaluation of available evidence by retinal specialists in consultation with medico legal and medical (immunology) colleagues.
- b. The Guidelines are for the pattern of practice rather than the care of a particular individual. While they may meet the needs of most patients, they cannot possibly meet the needs of all patients.
- c. Adherence to these Guidelines will not ensure a successful outcome in every situation and the Guidelines should not be deemed inclusive of all proper methods of care or exclusive of other methods of care reasonably directed at obtaining the best results overseas.

## 3 Patient information prior to Fluorescein and Indocyanine Green

### 3.1 Angiography

- a. The actual information provided to patients prior to FA, and the method of communication of this information, is at the discretion of the individual practitioner. It is considered that the following information is essential:
  - The reason for the FA being performed.
  - A description of the procedure
  - A description of potential risks of FA
- b. Written information is a helpful adjunct to any verbal explanation and increases retention of information by patients. A sample information sheet and consent form for FA is included with these Guidelines (see Appendix A). The information may be added to at the discretion of practitioners.

Note: If ICG Angiography is to be used, appropriate modification should be made to the sample FA information sheet/consent form (see Appendix A).

## 4 Informed Consent

FA is an invasive procedure that carries a small but definite risk of serious adverse effects including anaphylaxis and death. Informed consent is mandatory for such procedures. While there is no specific legal requirement for written informed consent, it is considered best

medical practice to document such consent in the patient's medical record, and consent forms are a useful aid in the documentation process.

## 5 Procedure

- a. The procedure of FA is well described in the literature and is beyond the scope of this document.
- b. The supervising medical practitioner may elect to delegate part/s of the procedure to appropriately trained personnel, but responsibility for the welfare of the patient remains with the medical practitioner.
- c. In patients with chronic renal failure, ophthalmologists may consider reducing dose of fluorescein due to risk of contrast-induced nephropathy. In high-risk patients, OCT angiography should be considered.

## 6 Probability of adverse events

- a. All ophthalmologists should be aware of the probability of adverse events in order to make informed decisions on the procedure. The following information has been obtained from the published literature.<sup>1-4</sup>

## 7 Common reactions<sup>1-4 5,6</sup>

- a. Nausea (2 to 3 per 100) Vomiting (1 to 2 per 1 00)
- b. Urticaria/pruritus (3 to 5 per 1000)
- c. Vasovagal reaction – low - reliable estimates not available
- d. Injection site complications – low - reliable estimates not available

## 8 Uncommon reactions

- a. Severe reactions – anaphylaxis, severe asthma/bronchospasm, cardiac arrhythmia, myocardial infarction, cardiac arrest, seizure (1:1,900 – 1:18,000)
- b. Death (1:50,000 to 1:222,000)

## 9 Management of adverse events

- a. Detailed management of all potential adverse events is beyond the scope of this document. RANZCO considers that the following are the minimum requirements for a practice or facility performing ophthalmic angiography:
  - Staff trained in the recognition and management of adverse reactions including anaphylaxis and cardiopulmonary arrest.
  - Regular updating and practice of staff in techniques of cardiopulmonary resuscitation
  - Equipment and medications to manage minor and major reactions, including anaphylaxis and cardiac arrest.
  - A protocol for contacting Emergency Services in the event of a severe adverse event

## 10 Reporting of adverse events

RANZCO encourages Fellows to report serious adverse reactions to intravenous fluorescein and/or ICG to ADRAC (the Adverse Drug Reaction Advisory Committee) using the form available online at <http://www.tga.gov.au/form/blue-card-adverse-reaction-reporting-form>.

## 11. Fluorescein Angiography in “high risk” patients

- a. Recognition of patients at high risk of anaphylactic reactions should be based on a careful history, particularly drug history and history of anaphylaxis and significant drug reactions. Allergy skin tests cannot predict non-immunological reactions but their utility remains substantial in predicting anaphylaxis during sodium fluorescein angiography (SFAs) and may be performed in patients reporting risk factors in their past medical history.<sup>7</sup>
- b. An adverse reaction to prior FA is highly predictive of further adverse reactions.<sup>4</sup>
- c. Patients with a history of severe adverse reaction to fluorescein, in whom further FA is considered medically essential, may require consultation with other medical colleagues, consideration of performing the angiogram in a hospital setting, and premedication to decrease the risk of hypersensitivity reactions. Successful desensitisation to fluorescein has been reported<sup>8</sup>, and this should only be considered in consultation with an experienced immunologist / allergist.
- d. Use of OCT angiography may be considered especially when looking for capillary non-perfusion. Wide field OCT (particularly those with wider scan field of 12 by 12mm or wider) is a reasonable option though it is recognised that access to these machines is limited outside of research or major eye institutions.
- e. For high-risk patients consider alternatives to standard dye-based Fluorescein angiography

## 12 Fluorescein Angiography during pregnancy

FA is generally avoided in patients known to be pregnant, although no definite teratogenic or other adverse effects on the unborn child have been documented as a result of FA<sup>9</sup>. OCT angiography may be a safe, non-invasive alternative. In certain circumstances it may be necessary to perform FA during pregnancy if it is felt that it is absolutely required, to allow treatment of sight threatening conditions.

## 13 Indocyanine Green Angiography

- a. Patient information, consent, and the precautions for ICG angiography are similar to those outlined for FA. The incidence of nausea and vomiting is less with ICG than fluorescein as the ICG preparation used for angiography is a compound containing iodide.
- b. The important point is there can be cross reaction if there is past history of an allergic reaction to iodide/iodine. Allergy to a compound containing iodide is considered a relative contraindication to ICG angiography. Caution is advised when performing angiography in patients with diabetes and renal impairment who are on metformin. If possible, they should not take metformin the morning of the procedure.

## 14 References

1. Butner R, McPherson, A. Adverse reactions in intravenous fluorescein angiography. *Ann Ophthalmol.* 1983;15:1084-1086.
2. Zografos L. Enquête internationale sur l'incidence des accidents graves ou fatals pouvant survenir lors d'une angiographie fluorescêinique. *J Fr Ophthalmology.* 1983;6:495-506.

3. Yanuzzi L, Rorher, K, Tindel, L, Sobel, R. Fluorescein angiography complication survey. *Ophthalmology*. 1986;93:611-617.
4. Kwiteroich K, Maguire, M, Murphy, R, Schachat, A. Frequency of adverse reactions after fluorescein angiography. *Ophthalmology*. 1991;98:1139-42.
5. Kwan A, Barry, C, McAllister, I, Constable, I. Fluorescein angiography and adverse drug reactions revisited – The Lions Eye experience. . *Clin Exp Ophthalmol*. 2006;34:33-38.
6. Lu V, Ho, I, Lee, V, Hunyor, A. Complications from fluorescein angiography: a prospective study. *Clinical & Experimental Ophthalmology*. 2009;37(8):826-7.
7. Kalogeromitros D, Makris, M, Aggelides, X, Mellios, A, Giannoula, F, Sideri, K, Rouvas, A, Theodossiadis, P. Allergy skin testing in predicting adverse reactions to fluorescein: a prospective clinical study. *Acta Ophthalmology*. 2011;89(5)doi: 10.1111/j.1755-3768.2009.01722.x
8. Nucere E, Schiavion, E, Merendino, E, Buonomo, A. Successful fluorescein desensitisation. *Allergy*. 2003;58:458.
9. Halperin L, Olk, R, Soubrane, G, Coscas, G,. Safety of fluorescein angiography during pregnancy. *Am J Ophthalmol*. 1990;109:563-566.

## 15 Record of amendments to this document

Page	Details of Amendment	Date amended
Entire document	Created	2007
Entire document	Reviewed	01/2012
Entire document	<ul style="list-style-type: none"> <li>• Reviewed</li> <li>• Wording of paragraphs 6 and 17 and page 6 updated</li> </ul>	06/2015
Entire document	<ul style="list-style-type: none"> <li>• Reviewed</li> <li>• Minor amendments throughout</li> </ul>	11/2018
Entire document	<ul style="list-style-type: none"> <li>• Reviewed</li> <li>• Minor amendments throughout</li> </ul>	04/2023

## Appendix A: SAMPLE FLUORESCEIN ANGIOGRAPHY INFORMATION SHEET AND CONSENT FORM

### What is Fluorescein Angiography?

Fluorescein angiography is a photographic test of the retina, the 'film' in the back of the eye. A water-soluble dye called fluorescein is injected into a vein in your arm, where it travels through the body reaching the eye. A special camera is used to take multiple photographs of the back of your eyes as the dye passes through the blood vessels, providing information about the retina and nearby tissues. Depending on the procedure employed, this may involve bright flashes of light.

### Why is Fluorescein Angiography performed?

Fluorescein angiography is used to diagnose certain eye conditions, determine if treatment is possible, and plan or guide treatment. Common conditions requiring fluorescein angiography include diabetic retinopathy, macular degeneration, and retinal vascular diseases. In some cases, the angiogram may need to be repeated to monitor your response to treatment or changes in your eye condition.

### What are the side effects of Fluorescein Angiography?

After fluorescein angiography, your skin will turn yellow for several hours. This will fade as the dye is filtered out by the kidneys – this leads to the urine turning a dark yellow-orange colour for up to 24 hours. Your vision will be blurred, and you should not drive for at least four hours after the angiogram, but there is no permanent effect on the vision from having the test done.

### Are there any risks?

Fluorescein angiography is a safe and very helpful test. Thousands of fluorescein angiograms are performed every year in Australia and New Zealand. The chance of adverse effects is low, but as with any medical procedure there are some risks involved. Some patients experience nausea during the angiogram, which usually passes within seconds. Some patients may vomit.

Occasionally some fluorescein will leak from a fragile vein, which may cause a localised burning feeling and yellow staining of the skin. The burning usually lasts a few minutes and the staining takes a few days to disappear.

Some patients may experience allergic reactions to the fluorescein dye. The most frequent allergic reaction is a skin rash, which is often itchy and may appear within minutes after the fluorescein injection. More severe allergic reactions are fortunately rare.

The most severe allergic reaction is called anaphylaxis, which is rare but may be life threatening. Very rarely patients may experience breathing difficulty or heart rhythm disturbances, which can be severe and even cause death. If you feel any itching, tingling in the lips or tongue, difficulty breathing or pain during or after the angiogram, let us know immediately. You may require medication to control the reaction, and your condition will be monitored until it has resolved. Delayed reactions are very uncommon, but it is important that you tell us if you experience any delayed effects that you feel may be related to your fluorescein angiogram.

Other information

It is very important for you to tell us about any health conditions that you have, all the medications that you are taking, and especially any allergies to medications that you have had in the past. It is preferred that you bring this information as a letter from your doctor. If you have had a previous fluorescein angiogram, please let us know. You do not need to fast for this test.

Fluorescein is reported to be safe in pregnancy, but we prefer to avoid this test in pregnant patients if possible. Please advise if you are pregnant or suspect you could be pregnant. If you have any further questions or concerns, please ask us before you have your angiogram.

CONSENT TO FLUORESCEIN ANGIOGRAPHY

I, \_\_\_\_\_ have read, or have had read to me, the above information concerning the procedure of fluorescein angiography. I understand this information, and any questions that I have asked have been answered to my satisfaction.

I consent to the procedure being performed \_\_\_\_\_

Witness

\_\_\_\_\_